<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7249615\results\search\testTrace\results.xml">
  <result pre="pmcid: 72496152383 doi: 10.1007/s11739-020-02383-3 : Im - Review Potential new" exact="treatment" post="strategies for COVID-19: is there a role for bromhexine"/>
  <result pre="brought attention to the possible benefit of chloroquine in the" exact="treatment" post="of patients infected by SARS-CoV-2. Whether chloroquine can treat"/>
  <result pre="main replication and distribution center for the CoVs. A potential" exact="treatment" post="should, therefore, first target the lungs to prevent a"/>
  <result pre="should, therefore, first target the lungs to prevent a generalized" exact="infection" post="or at least mitigate the symptoms. ACE2 is also"/>
  <result pre="an important entry point for SARS-CoV-2 and that the first" exact="infection" post="with SARS-CoV-2 may have resulted from eating food from"/>
  <result pre="route of transmission, the containment of the virus spread, and" exact="treatment" post="for it [20]. The distribution of ACE2 tissue in"/>
  <result pre="could also explain expansion of dysfunction observed in patients. Potential" exact="treatment" post="strategies for COVID-19 The topic of clinical management of"/>
  <result pre="(FM) supplemental oxygen and their response monitored closely. Currently, the" exact="treatment" post="is mainly symptomatic and supportive care, and for patients"/>
  <result pre="mainly symptomatic and supportive care, and for patients with severe" exact="infection" post="oxygen therapy represents the major treatment intervention. Preventive strategies"/>
  <result pre="for patients with severe infection oxygen therapy represents the major" exact="treatment" post="intervention. Preventive strategies aimed at reducing transmission are focused"/>
  <result pre="Preventive strategies aimed at reducing transmission are focused on the" exact="isolation" post="of patients and careful infection control. Vaccine development against"/>
  <result pre="transmission are focused on the isolation of patients and careful" exact="infection" post="control. Vaccine development against SARS-CoV-2 is in advanced stages"/>
  <result pre="cells, it is the main target of neutralizing antibodies upon" exact="infection" post="and the focus of therapeutic and vaccine design. The"/>
  <result pre="mesilate, a TMPRSS2 inhibitor. It is currently only approved for" exact="treatment" post="of chronic pancreatitis in Japan [27]. Very little data"/>
  <result pre="selective TMPRSS2. Camostat mesilate is currently undergoing Phase 1/2 trial" exact="testing" post="in the USA for chronic pancreatitis [28]. If deemed"/>
  <result pre="pancreatitis [28]. If deemed safe, it could be a potential" exact="treatment" post="option of CoV infections [29]. Nafamostat mesilate is also"/>
  <result pre="well as autoimmune diseases. Chloroquine is known to block virus" exact="infection" post="by increasing endosomal pH required for virus/endosome fusion [38]"/>
  <result pre="novel class of autophagy inhibitor, [40] further interfering with viral" exact="infection" post="and replication. A combination of remdesivir and chloroquine was"/>
  <result pre="system (RAS) [47], additionally protecting the lungs from injuries. Therefore," exact="treatment" post="with a soluble form of ACE2 could slow down"/>
  <result pre="is inhibited by an elevated endosomal pH and, thus, chloroquine" exact="treatment" post="will also work [52]. Interference with viral replication Interference"/>
  <result pre="not be confirmed in a recent clinical trial as a" exact="treatment" post="in adults with SARS-CoV-2. Their results demonstrated no difference"/>
  <result pre="a pandemic like COVID-19? A prophylaxis strategy and a suitable" exact="treatment" post="for the emerging SARS-CoV-2 are crucial for reducing the"/>
  <result pre="patients as they have gone through rigorous safety and risk" exact="testing" post="and are already approved as safe for human use."/>
  <result pre="of 96Â mg (32Â mg tid) BHT combined with standard" exact="treatment" post="(experimental group) compared to standard treatment alone (control group)"/>
  <result pre="BHT combined with standard treatment (experimental group) compared to standard" exact="treatment" post="alone (control group) in suspected patients and confirmed patients"/>
  <result pre="that bromhexine hydrochloride may have a good effect on the" exact="treatment" post="of COVID-19. Recent publications on COVID-19 have brought attention"/>
  <result pre="brought attention to the possible benefit of chloroquine in the" exact="treatment" post="of patients infected by SARS-CoV-2. Whether chloroquine can treat"/>
  <result pre="way to see if chloroquine can be effective in the" exact="treatment" post="of COVID-19. Chloroquine had been approved for â€œcompassionate useâ€�"/>
  <result pre="not work [71â€&quot;73]. Treatment with chloroquine did not prevent influenza" exact="infection" post="in a randomized, double-blind, placebo-controlled clinical trial [74]. Conversely,"/>
  <result pre="discussed glycosylation of the binding pocket [38]. After the viral" exact="infection" post="has spread in the body and due to the"/>
  <result pre="inhibiting cathepsin B/L, could be a favorable combination for the" exact="treatment" post="of moderate-to-severe COVID-19 cases. The addition of the 3CLpro"/>
  <result pre="prophylaxis is 400Â mg per week and for a curative" exact="treatment" post="a loading dose of 800Â mg (twice daily 400Â"/>
  <result pre="airway epithelial cells at remarkably lower concentrations compared to a" exact="treatment" post="with each inhibitor alone [80]. One can deduce that"/>
  <result pre="considered as additional support to current and also our proposed" exact="treatment" post="scheme [51] (Fig. 3) Fig. 3 Hostâ€&quot;virus interaction: how"/>
  <result pre="with HCQ and/or quercetin as an immediately available and affordable" exact="treatment" post="option or prophylactic use in response to the COVID-19"/>
  <result pre="in China, 2019N Engl J Med2020382872773310.1056/NEJMoa200101731978945 8.CascellaMRajnikMCuomoADulebohnSCDi NapoliRFeatures, evaluation and" exact="treatment" post="coronavirus (COVID-19)2020St. PetersburgStatPearls Publishing 9.WuFZhaoSYuBChenYMWangWSongZGet al.A new coronavirus associated"/>
  <result pre="is an essential regulator of heart functionNature2002417689182282810.1038/nature0078612075344 18.GuJGongEZhangBZhengJGaoZZhongYet al.Multiple organ" exact="infection" post="and the pathogenesis of SARSJ Exp Med2005202341542410.1084/jem.2005082816043521 19.HashimotoTPerlotTRehmanATrichereauJIshiguroHPaolinoMet al.ACE2"/>
  <result pre="distress syndrome: the Berlin DefinitionJAMA2012307232526253310.1001/jama.2012.566922797452 22.GattinoniLChiumelloDCaironiPBusanaMRomittiFBrazziLet al.COVID-19 pneumonia: different respiratory" exact="treatment" post="for different phenotypes?Intensive Care Med202010.1007/s00134-020-06033-232291463 23.Craven J (2020) Covid-19"/>
  <result pre="for a randomized controlled trial on the assessment of camostat" exact="treatment" post="in chronic pancreatitis (TACTIC)Trials201920150110.1186/s13063-019-3606-y31412955 29.ZhouYVedanthamPLuKAgudeloJCarrionRNunneleyJWet al.Protease inhibitors targeting coronavirus"/>
  <result pre="Resist20188345946410.1016/j.ijpddr.2018.10.00230396013 38.VincentMJBergeronEBenjannetSEricksonBRRollinPEKsiazekTGet al.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J2005216910.1186/1743-422X-2-6916115318 39.JangCHChoiJHByunMSJueDMChloroquine inhibits production of TNF-alpha, IL-1beta"/>
  <result pre="(2019-nCoV) in vitroCell Res202030326927110.1038/s41422-020-0282-032020029 42.GautretPLagierJCParolaPHoangVTMeddedLMailheMet al.Hydroxychloroquine and Azithromycin as a" exact="treatment" post="of COVID-19: preliminary results of an open-label non-randomized clinical"/>
  <result pre="less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2" exact="infection" post="in vitroCell Discov2020611610.1038/s41421-020-0156-032194981 47.KubaKImaiYRaoSGaoHGuoFGuanBet al.A crucial role of angiotensin"/>
  <result pre="of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual" exact="screening" post="reveals velpatasvir, ledipasvir, and other drug repurposing candidatesF1000Res2020912910.1288/f1000research.22457.132194944 59.LimJJeonSShinHYKimMJSeongYMLeeWJet"/>
  <result pre="of the index patient who caused tertiary transmission of COVID-19" exact="infection" post="in Korea: the application of lopinavir/ritonavir for the treatment"/>
  <result pre="COVID-19 infection in Korea: the application of lopinavir/ritonavir for the" exact="treatment" post="of COVID-19 infected pneumonia monitored by quantitative RT-PCRJ Korean"/>
  <result pre="new scientific data on ambroxol in the context of the" exact="treatment" post="of bronchopulmonary diseasesMMW Fortschritte der Medizin2017159Suppl 5223310.1007/s15006-017-9805-028643291 65.GaoXHuangYHanYBaiC-XWangGThe protective"/>
  <result pre="71.KeyaertsELiSVijgenLRysmanEVerbeeckJVan RanstMet al.Antiviral activity of chloroquine against human coronavirus OC43" exact="infection" post="in newborn miceAntimicrob Agents Chemother20095383416342110.1128/aac.01509-0819506054 72.TanYWYamWKSunJChuJJHAn evaluation of chloroquine"/>
  <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal modelCell Res201323230030210.1038/cr.2012.16523208422 74.PatonNILeeLXuYOoiEECheungYBArchuletaSet al.Chloroquine for influenza"/>
  <result pre="and projection of optimized dosing design of hydroxychloroquine for the" exact="treatment" post="of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Clin Infect"/>
  <result pre="activating host cell proteases provide promising drug targets for the" exact="treatment" post="of influenza A and B virus infectionsVaccine201230517374738010.1016/j.vaccine.2012.10.00123072892"/>
 </snippets>
</snippetsTree>
